Piramal Pharma Ltd Q1 FY27 Results

Delivered ₹2269.9 Cr, +17.4% YoY

EBITDA +12.5% margin (+400 bps), but PAT -₹69.4 Cr (-2.9% NPM)

Consistent with 12.5% margin on ₹2270 Cr revenue

CDMO +19% YoY, CHG +17% YoY, Consumer Healthcare mid-teens (Power Brands +23%)

17% YoY growth but Peter DeYoung noted Chinese competitive pressure continues; ex-US growth offset muted US base

12.5% vs. prior OPM ~8.6%, delivering promised 400 bps. No change to FY30 25% target, so improvement is on track.

Peter DeYoung reaffirmed full-year CHG guidance despite Q1 17% beat. Cautions 'exact percentage rate in Q1 won't be full-year number' due to historical H2 loading.

CEO reports 'meaningful increase in RFP activity', 'robust order inflow', and 'significant portion' directed to overseas sites—language stronger than prior calls, but no numeric guidance change.

Was expecting sharp normalization; now 'will remain elevated in FY27' due to R&D disallowance. Normalization deferred to 'years ahead' as subs scale.

Vivek: Began with stronger opening order book. But ups/downs quarter-to-quarter depend on delivery patterns. Maintaining annual guidance; it's early days.

Peter: Chinese competitive pressure remains. Our actions have started to bear fruit. Reaffirm full-year guidance, but don't assume Q1 rate = full-year.

Peter: Top 20 customers growing faster than rest of business. Many work across multiple sites. Land-and-expand is core strategy—growth accelerates with largest customers.

Vivek: Quarterly gross margin not indicative of annual. Overseas typically 75–85%, India 55–65%, blended 64–65%. At EBITDA level, India and overseas margins comparable at scale.

Vivek: Higher incidence of profit in tax-paying jurisdictions + R&D credit disallowance. Don't pay tax higher than jurisdiction rates (India <25%, US <21%). Normalized rate 24–25% at scale; elevated now due to scale mismatch.

Peter: Differentiated growing faster than overall; investing more behind them. Biggest driver of EBITDA margin = operating leverage at scale + mix of differentiated and on-patent offerings.

Peter: Single to low double-digit revenue potential. Immediately available; already have customers siding in. Less than $5M investment; single room in larger high-potent API facility.

Vivek: USD120–135M annual capex guidance; spent USD21M in Q1. Lexington on track for CY2027 end. Spends progressing as per plan.

Peter: Historically share this annually. Evaluating interim updates. Don't share individual/aggregate forecasts. Late-stage programs typically larger; 50% chance to commercial, would be meaningful contributors.

Nandini: Increased utilization will help achieve operating leverage and break even. Vivek: Significant carry-forward tax losses across North America, UK, Europe; some recognized as deferred tax assets; others yet to recognize. Gradual shift, not upfront.

Peter: Not really near-shoring-driven. Four reasons for optimism: improved operational performance (NPS 60), larger BD team, commercial transformation, and customers have money to spend. Spike in near-shore interest above baseline.

Peter: API and drug product made in Bethlehem, Pennsylvania. Inputs from India; can send from Dahej direct or process at Digwal then Bethlehem. Final stages in US. Reasonably well-positioned for tariff outcomes.

Historically CDMO and CHG deliver higher H2 vs H1. Q1 benefited from stronger opening order book. Vivek cautioned 'early days' for revision; will revisit post-Q2.

400 bps expansion demonstrated via operating leverage, pricing discipline, capacity utilization. Vivek confirmed CDMO also targets similar 25% range by FY30.

Riverview done; Lexington on track. Capex spans integrated ADC platform (payload-linker + sterile fill-finish). USD21M spent Q1.

11 overseas subs carry ₹146 Cr accumulated losses. Breakeven depends on utilization ramp and operating leverage. No specific timeline given; tied to FY30 margin target.

Net loss ₹69.4 Cr in Q1 despite 12.5% EBITDA margin; capex depreciation, R&D tax credit disallowance, and sub scale dilution explain gap. PAT unlikely to turn positive until FY28+.

Chinese competition in CHG continues; management actions bearing fruit (ex-US growth offset muted US base), but sustainability uncertain. Q1 17% may not repeat full-year.

155 active molecules pipeline; 25 in commercial stage with 50% clinical success rate. Revenue potential of late-stage programs not disclosed. New Amsterdam cholesterol drug contract timing uncertain.

Effective tax rate elevated due to R&D credit disallowance in overseas facilities; appeal filed. Normalization to 24–25% deferred; 'not a sharp reduction' in FY27.